Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AGIO · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Depend… NCT04770753 · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusio… Placebo Matching Mitapivat, Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 194 | Nov 13, 2023 | Registry ↗ |
| Oct 29, 2026 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Partici… NCT07506863 · Transfusion-dependent Alpha-Thalassemia, Transfusion-depend… Mitapivat Matched Placebo, Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | 54 | Jun 2029 | Registry ↗ |
| Oct 28, 2026 | A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell D… NCT07656415 · Sickle Cell Disease Mitapivat Matched Placebo, Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | 159 | Aug 2029 | Registry ↗ |
| Oct 28, 2026 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Partici… NCT07517133 · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusio… Mitapivat, Placebo Matching Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | 45 | Mar 2029 | Registry ↗ |
| Oct 28, 2026 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subje… NCT07241234 · Phenylketonuria AG-181 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Recruiting | 20 | Jan 17, 2028 | Registry ↗ |
| Oct 28, 2026 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell D… NCT06924970 · Sickle Cell Disease Tebapivat, Tebapivat Matched Placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 2 | Active, not recruiting | 59 | May 12, 2026 | Registry ↗ |
| Oct 28, 2026 | A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Spo… NCT05777993 · Pyruvate Kinase Deficiency, Anemia, Hemolytic Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 4 | Enrolling by invitation | 55 | Aug 2029 | Registry ↗ |
| Oct 28, 2026 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Ki… NCT05175105 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic A… Mitapivat, Mitapivat-matching placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 30 | Dec 13, 2024 | Registry ↗ |
| Oct 28, 2026 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Ki… NCT05144256 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic A… Mitapivat, Mitapivat-matching placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 49 | May 3, 2024 | Registry ↗ |
| Oct 28, 2026 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent… NCT04770779 · Transfusion-dependent Alpha-Thalassemia, Transfusion-depend… Placebo Matching Mitapivat, Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 258 | Apr 11, 2024 | Registry ↗ |
| Oct 28, 2026 | Pyruvate Kinase Deficiency Global Longitudinal Registry NCT03481738 · Pyruvate Kinase Deficiency | AGIO Agios Pharmaceuticals, Inc. | — | Active, not recruiting | 500 | May 31, 2027 | Registry ↗ |
| Oct 26, 2026 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell D… NCT05031780 · Sickle Cell Disease Mitapivat, Mitapivat-matching placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 2/3 | Active, not recruiting | 286 | Oct 30, 2025 | Registry ↗ |
| Oct 13, 2026 | A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera NCT07859423 · Polycythemia Vera AG-236, Placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 2/3 | Not yet recruiting | 245 | Aug 2030 | Registry ↗ |
| Sep 28, 2026 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndrom… NCT05490446 · Myelodysplastic Syndromes Tebapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 2 | Active, not recruiting | 87 | Mar 17, 2026 | Registry ↗ |
| Jul 30, 2026 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and… NCT07075640 · Healthy Participants AG-236, Placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Active, not recruiting | 24 | Feb 11, 2026 | Registry ↗ |
| May 1, 2026 | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency NCT02476916 · Pyruvate Kinase Deficiency AG-348 | AGIO Agios Pharmaceuticals, Inc. | Phase 2 | Completed | 52 | May 8, 2017 | Registry ↗ |
| Apr 3, 2026 | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy NCT06286046 · Sickle Cell Disease, Nephropathy Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 2 | Withdrawn | 0 | May 2027 | Registry ↗ |
| Mar 30, 2026 | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adul… NCT03692052 · Thalassemia AG-348 | AGIO Agios Pharmaceuticals, Inc. | Phase 2 | Active, not recruiting | 20 | Aug 20, 2020 | Registry ↗ |
| Dec 23, 2025 | Single and Multiple Ascending Dose Study and Food Effect Study for AG181 NCT06286033 · Healthy Volunteers AG-181, Placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 88 | Oct 9, 2025 | Registry ↗ |
| Nov 18, 2025 | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled… NCT03853798 · Pyruvate Kinase Deficiency Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Completed | 90 | Jul 3, 2024 | Registry ↗ |
| Mar 18, 2025 | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Exte… NCT06745271 · Healthy Participants [14C]-tebapivat, [13C2,15N3]-tebapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 8 | Feb 21, 2025 | Registry ↗ |
| Jan 28, 2025 | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants NCT06648824 · Healthy Participants Mitapivat, Midazolam | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 20 | Dec 3, 2024 | Registry ↗ |
| Apr 16, 2024 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Hea… NCT04536792 · Healthy Volunteers, Anemia, Sickle Cell AG-946, AG-946 Matched Placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 122 | Dec 19, 2023 | Registry ↗ |
| Oct 16, 2023 | Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008 NCT04995315 · Pyruvate Kinase Deficiency | AGIO Agios Pharmaceuticals, Inc. | — | Completed | 13 | Sep 22, 2023 | Registry ↗ |
| Sep 21, 2023 | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to M… NCT05610657 · Moderate Hepatic Impairment Mitapivat | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 20 | Jul 21, 2023 | Registry ↗ |
| Sep 7, 2023 | Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) NCT04964323 · Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anem… | AGIO Agios Pharmaceuticals, Inc. | — | Terminated | 15 | Jun 30, 2023 | Registry ↗ |
| May 24, 2022 | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants Wi… NCT03548220 · Pyruvate Kinase Deficiency, Anemia, Hemolytic Placebo, AG-348 | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Completed | 80 | Oct 9, 2020 | Registry ↗ |
| Jan 4, 2022 | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants Wit… NCT03559699 · Pyruvate Kinase Deficiency, Anemia, Hemolytic AG-348 | AGIO Agios Pharmaceuticals, Inc. | Phase 3 | Completed | 27 | Nov 12, 2020 | Registry ↗ |
| Jul 21, 2021 | A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect… NCT04128787 · Healthy Volunteers AG881 Formulation 1, AG881 Formulation 2 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 36 | Dec 18, 2019 | Registry ↗ |
| Apr 13, 2021 | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mita… NCT04696393 · Healthy Volunteers Mitapivat tablet | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 26 | Mar 19, 2021 | Registry ↗ |
| Feb 18, 2021 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy… NCT04472832 · Healthy Volunteers Placebo for Treatment A, Mitapivat 100 mg | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 32 | Nov 23, 2020 | Registry ↗ |
| Dec 10, 2020 | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation… NCT04565678 · Healthy Volunteers Mitapivat tablets, Mitapivat coated granules | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 32 | Dec 3, 2020 | Registry ↗ |
| Aug 25, 2020 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma NCT03834584 · Lymphoma AG-636 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Terminated | 11 | Jun 17, 2020 | Registry ↗ |
| Apr 2, 2020 | A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants NCT04145128 · Healthy Volunteers AG881 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 32 | Dec 11, 2019 | Registry ↗ |
| Mar 16, 2020 | Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma NCT03361358 · Advanced Solid Tumors, Lymphoma | AGIO Agios Pharmaceuticals, Inc. | — | Completed | 44 | Sep 30, 2019 | Registry ↗ |
| Oct 23, 2019 | Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Phar… NCT03991312 · Healthy Volunteers itraconazole, rifampin | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 28 | Aug 14, 2019 | Registry ↗ |
| Oct 23, 2019 | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration… NCT03960502 · Healthy Male Participants AG-881, [13C315N3]AG-881 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 5 | Sep 7, 2019 | Registry ↗ |
| Oct 14, 2019 | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in… NCT04015687 · Healthy Participants AG-881, Lamotrigine | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 22 | Oct 9, 2019 | Registry ↗ |
| Mar 8, 2019 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1… NCT02492737 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome AG881 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 46 | Mar 21, 2018 | Registry ↗ |
| Oct 12, 2018 | A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailabilit… NCT03703505 · Healthy Volunteers AG-348, [13C6]AG-348 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 8 | Jun 1, 2018 | Registry ↗ |
| Jul 24, 2018 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation NCT03245424 · Acute Myeloid Leukemia, Relapsed Adult AML ivosidenib (AG-120) | AGIO Agios Pharmaceuticals, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Apr 27, 2018 | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepat… NCT03282513 · Hepatic Impairment AG-120 (Ivosidenib) | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 33 | Mar 31, 2018 | Registry ↗ |
| Jan 12, 2018 | Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulat… NCT03397329 · Healthy Volunteers AG-348 Sequence A, AG-348 Sequence B | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 26 | Nov 13, 2017 | Registry ↗ |
| Jan 11, 2018 | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects NCT03071770 · Healthy ivosidenib (AG-120) | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 60 | May 9, 2017 | Registry ↗ |
| Oct 19, 2017 | Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Jap… NCT03250598 · Healthy, Japanese AG-348, AG-348 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 60 | Oct 2, 2017 | Registry ↗ |
| Jun 29, 2017 | A Safety and Tolerability Study of AG-519 in Healthy Subjects NCT02630927 · Anemia AG-519, Placebo | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Terminated | 108 | Dec 2016 | Registry ↗ |
| Jun 27, 2017 | Drug-Drug Interaction Study of AG120 in Healthy Subjects NCT02831972 · Healthy AG120, Itraconazole | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 22 | Sep 2016 | Registry ↗ |
| Nov 29, 2016 | Food Effect Study of AG120 in Healthy Subjects NCT02579707 · Healthy AG120 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 36 | Feb 2016 | Registry ↗ |
| Dec 14, 2015 | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 NCT02489513 · Healthy Volunteers [14C]-AG-120 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 8 | Sep 2015 | Registry ↗ |
| Dec 14, 2015 | Food Effect Study of AG-221 in Healthy Male Subjects NCT02218346 · Healthy Volunteers AG221 | AGIO Agios Pharmaceuticals, Inc. | Phase 1 | Completed | 30 | Dec 2014 | Registry ↗ |
50 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances